Coya Therapeutics, Inc. (COYA) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Coya Therapeutics, Inc. had $32.6 million in cash and cash equivalents at the end of 2023, which increased to $40.1 million after receiving $7.5 million from Dr. Reddy’s Laboratories Ltd. in January 2024, based on a prior agreement. The company may receive an additional $8.4 million from Dr. Reddy’s upon FDA acceptance of an IND application and the start of Phase 2 trials for COYA 302, a treatment for ALS, with anticipated milestones in the first and second halves of 2024, respectively. The current funds are expected to sustain the company’s operations into 2026.
For further insights into COYA stock, check out TipRanks’ Stock Analysis page.